Dissociation-enhanced lanthanide fluorescent immunoassay

Pro-inflammatory cytokines are important mediators of inflammation and tissue destruction. This section describes two cell-based assays that were used to screen for inhibitors of cytokine production and some of the compounds discovered using these screens. The two screens were important elements of a collaboration between Xenova Ltd and the Suntory Institute of Biomedical Research to find microbial metabolites with potential utility for the treatment of rheumatoid arthritis. Both screens were cell stimulatory assays with similar formats, the principle of which is illustrated in Figure 3. Treatment of cells with a particular stimulus activates a signal transduction pathway, one of the end results of which is production of a cytokine, which is secreted into the assay medium. After a separation step, the cytokine of interest is measured quantitatively in the supernatant by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA) using a europium-labeled tertiary antibody. At the same time, cytotoxic properties of test substances are determined by assessing their effect on proliferation of the separated cells. 

On this basis, the dissociation-enhanced lanthanide fluorescence immunoassay was developed. Mostly a two-site assay format is used whereby antibodies are immobilized at microtiter plates and after applying the sample antigen, europium-chelate-labeled antibodies bind to the sample. A commonly used chelating reagent is Nl-(p-isothiocyanato-benzyl)-diethylene triamine. After the addition of a S-diketone as a dissociation enhancer, at acidic pH, europium is released and fluorescence of Eu is measured. Other TRFIAs use stabilized lanthanide chelates or stable chelates. 

Different variations of time-resolved luminescence assays were patented in 1982 by Wieder [1], in 1983 by Soini and HemmUa [2], and in 1999 by Diamandis [3]. The Finnish company Wallac first commercialized the principle and introduced an assay reader for dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) in the beginning of the 1980s. The first (1982) DELFIA-based bioassay for diagnostic market was for Rubella antibodies, and it was the first sensitive nonradioisotope innnunoassay marking the beginning of a new era [4]. 

---